Ultra-long-acting insulins for a lifestyle-related pandemic

The Lancet

Volumn 377, Issue 9769, 2011, Pages 880-881

  Kudva, Yogish C ^a   Basu, Ananda ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN DERIVATIVE; LONG ACTING DRUG;

HUMAN; INSULIN TREATMENT; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PANDEMIC; PRIORITY JOURNAL;

EID: 79952484088     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60097-4     Document Type: Note

References (12)

1. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34. (Pubitemid 28350165)
2. Cowie CC, Rust KF, Ford ES, et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care 2009; 32: 287-94.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
4. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59.
5. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-72.
6. Duckworth W, Abraira C, Moritz T, et al, for the VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-39.
7. US Food and Drug Administration. Guidance for industry. Diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. December, 2009. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf (accessed Jan 14, 2011).
8. Hoerger TJ, Segal JE, Gregg EW, Saaddine JB. Is glycemic control improving in US adults? Diabetes Care 2008; 31: 81-86.
9. Russell LB, Suh DC, Safford MA. Time requirements for diabetes self-management: too much for many? J Fam Pract 2005; 54: 52-56. (Pubitemid 40105222)
10. Zinman B, Fulcher G, Rao PV, et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet 2011; published online March 10. DOI:10.1016/S0140-6736(10)62305-7.
11. Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010; 375: 2234-43.
12. Johnson JA, Gale EA. Diabetes, insulin use, and cancer risk: are observational studies part of the solution - or part of the problem? Diabetes 2010; 59: 1129-31.